Gregory G. Schwartz

Orthopedics

909 Southeast Pkwy Ste 103
Azle, TX 76020

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 168 publications

The safety of low lipoprotein(a): a story not yet fully told.

The safety of low lipoprotein(a): a story not yet fully told.

Journal: European heart journal

Published: August 05, 2026

Relation of lipoprotein(a) levels with risk of serious bleeding in the ODYSSEY OUTCOMES trial.

Relation of lipoprotein(a) levels with risk of serious bleeding in the ODYSSEY OUTCOMES trial.

Journal: European journal of preventive cardiology

Published: July 18, 2026

Nivolumab in combination with lenvatinib in unresectable hepatocellular carcinoma: The IKF-t006/IMMUNIB translational phase-2 study.

Nivolumab in combination with lenvatinib in unresectable hepatocellular carcinoma: The IKF-t006/IMMUNIB translational phase-2 study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 28, 2026

Adaptive AI for Cardiovascular Event Adjudication: Cardiovascular Event Adjudication Across Different Definitions in the ODYSSEY OUTCOMES and EUCLID Trials.

Adaptive AI for Cardiovascular Event Adjudication: Cardiovascular Event Adjudication Across Different Definitions in the ODYSSEY OUTCOMES and EUCLID Trials.

Journal: Circulation

Published: March 30, 2026

LDL Cholesterol: How Low to Go?

LDL Cholesterol: How Low to Go?

Journal: Journal of the American College of Cardiology

Published: February 18, 2026

Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes After Acute Coronary Syndrome.

Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes After Acute Coronary Syndrome.

Journal: Circulation

Published: December 01, 2025

Interleukin-6 and C-reactive protein prognostic value following acute coronary syndrome.

Interleukin-6 and C-reactive protein prognostic value following acute coronary syndrome.

Journal: European heart journal

Published: October 10, 2025

Multiplex Apolipoprotein Panel Improves Cardiovascular Event Prediction and Cardiovascular Outcome by Identifying Patients Who Benefit From Targeted PCSK9 Inhibitor Therapy.

Multiplex Apolipoprotein Panel Improves Cardiovascular Event Prediction and Cardiovascular Outcome by Identifying Patients Who Benefit From Targeted PCSK9 Inhibitor Therapy.

Journal: Arteriosclerosis, thrombosis, and vascular biology

Published: September 25, 2025

Small, dense LDL-C as a predictor of cardiovascular risk and benefit of alirocumab in patients with recent acute coronary syndrome receiving optimized statin treatment.

Small, dense LDL-C as a predictor of cardiovascular risk and benefit of alirocumab in patients with recent acute coronary syndrome receiving optimized statin treatment.

Journal: American journal of preventive cardiology

Published: September 16, 2025

Inclisiran in Patients with CKD: Post Hoc Pooled Analysis of Three Phase 3 Trials.

Inclisiran in Patients with CKD: Post Hoc Pooled Analysis of Three Phase 3 Trials.

Journal: Journal of the American Society of Nephrology : JASN

Published: September 09, 2025

Inclisiran in Patients with CKD: Post Hoc Pooled Analysis of Three Phase 3 Trials.

Inclisiran in Patients with CKD: Post Hoc Pooled Analysis of Three Phase 3 Trials.

Journal: Journal of the American Society of Nephrology : JASN

Published: September 09, 2025

Effect of PCSK9 Inhibition With Alirocumab in Patients With Probable Familial Hypercholesterolemia or Type III Hyperlipoproteinemia: Results From the ODYSSEY OUTCOMES Trial.

Effect of PCSK9 Inhibition With Alirocumab in Patients With Probable Familial Hypercholesterolemia or Type III Hyperlipoproteinemia: Results From the ODYSSEY OUTCOMES Trial.

Journal: Journal of the American Heart Association

Published: August 23, 2025

Showing 1-12 of 168

Last Updated: 09/26/2026